Healthcare Industry News: Miramar Labs
News Release - October 13, 2008
Miramar Labs Names Zoromski As CEOMENLO PARK, Calif., Oct. 13 -- (Healthcare Sales & Marketing Network) -- Miramar Labs (http://www.miramarlabs.com/), a startup dermatologic medical device company based in Menlo Park, CA, has named Darrell Zoromski as President and CEO. Zoromski joins Miramar from Align Technology, where he was Chief Marketing Officer and Global Vice President. Align is a global manufacturer and distributor of Invisalign-branded aligner trays that straighten teeth.
"Darrell brings an impressive record of entrepreneurial marketing leadership to Miramar," says Mark Deem, Interim President & CEO of Miramar and Chief Technology Officer of The Foundry, where Miramar Labs was incubated. Prior to his position at Align, Zoromski held marketing management positions of increasing responsibilities at Sola/Zeiss Vision Company, Pillsbury, S.C. Johnson, and Proctor & Gamble. Notes Deem: "At each stop in his career, Darrell has led the establishment of innovative new technologies while growing market share and profitability." Zoromski is a graduate of the Kellogg Graduate School of Management at Northwestern University, where he earned is MBA in marketing, and of the University of Wisconsin, where he earned his BA in finance, international business and marketing.
Miramar was launched in 2006 with a Series "A" round financing of $5 million from The Foundry's two venture capital backers, Morgenthaler Ventures and Split Rock Partners. In February 2008, Domain Associates led a "B" round financing of $22-million, in which Morgenthaler, and Split Rock also invested.
Miramar represents the 11th company incubated at The Foundry (www.the-foundry.com), widely recognized as the world's premier medical device incubator. Founded in 1998, The Foundry has created such companies as Concentric Medical, Emphasys, Evalve, Satiety, Xtent, which have combined valuations of over $1-billion and employ more than 600 people.
Source: Miramar Labs
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.